VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030, and an increase in the maximum size of the board of directors from five to seven members.
The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities, and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
This announcement signals a pivotal moment for VERAXA as it gains the structural flexibility needed to execute its ambitious plans. The capital band, extending to 2030, allows the company to issue shares up to a certain limit without further shareholder approval, enabling swift responses to market opportunities. The expanded board can bring in additional expertise to guide strategic decisions, particularly as the company advances its pipeline of bispecific T cell engagers and antibody-drug conjugates (ADCs).
VERAXA’s proprietary BiTAC technology aims to improve cancer treatment by engaging T cells to target and destroy tumor cells. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. With a strong cash position and now enhanced financing capabilities, VERAXA is well-positioned to accelerate clinical development and explore strategic partnerships.
The overwhelming shareholder approval, with 99.94% in favor, underscores confidence in the management’s direction. The company noted that the measures are not immediately dilutive but provide a toolkit for future capital raising when needed. This vote removes potential hurdles in future transactions, allowing VERAXA to act quickly in a competitive biotech landscape.
For investors, the implications are clear: VERAXA now has the corporate governance and financing flexibility to pursue growth without frequent shareholder votes. This could lead to faster progress in the clinic and potential value-creating deals. The company continues to focus on developing next-generation antibody-based therapeutics, aiming to address unmet needs in oncology. As the biotech sector faces a challenging financing environment, VERAXA’s proactive approach to securing flexibility may set it apart.
